Valve & Structural Course

September 12 - October 17

Join experts in the field of structural heart disease to explore the significant advances in the application of percutaneous procedures for structural heart disease. Gain knowledge of available and emerging devices, along with clinical evidence, that can assist in the identification of patients likely to benefit from structural heart interventions.

Learning Objectives

  • Appraise percutaneous devices from concept through preclinical and clinical investigation, regulatory approval and clinical application for the treatment of structural heart and valve disease
  • Describe appropriate pharmacologic management in the care of patients undergoing diagnostic arteriography and interventional therapies before, during and after cardiac catheterization
  • Compare the results from important clinical trials and evidence-based medicine to guide management of patients with atherosclerosis and structural heart disease

View Agenda

Call for Complications

CRTvirtual IS LOOKING FOR COMPLEX CASES TO BE PRESENTED ON SATURDAY, OCTOBER 17, 2020, FROM 8:00 A.M. – 10:00 A.M.

  • The Top 10 Cases will be selected for 10-minute presentations, followed by 5-minute Q&A sessions.
  • Deadline: All Complications Cases must be submitted electronically by 11:59 P.M. EDT on Tuesday, September 15, 2020.

Call for Complications​

CRTvirtual IS LOOKING FOR COMPLEX CASES TO BE PRESENTED ON SATURDAY, OCTOBER 17, 2020, FROM 8:00 A.M. - 10:00 A.M.

  • The Top 10 Cases will be selected for 10-minute presentations, followed by 5-minute Q&A sessions.
  • Deadline: All Complications Cases must be submitted electronically by 11:59 P.M. EDT on Tuesday, September 15, 2020.

Target Audience

Interventional cardiologists, clinical cardiologists, cardiac surgeons, interventional cardiology fellows, vascular surgeons, nurses, technologists, industry professionals and other health care professionals who want to enhance their knowledge of structural heart disease and coronary interventions and the treatment of patients with structural heart disease.